Pamudurti, N. R. et al. Translation of CircRNAs. Mol. Cell. 66, 9 (2017).
Zhang, M. et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene 37, 1805–1814 (2018).
Zhang, M. et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat. Commun. 9, 4475 (2018).
Liang, W. et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 20, 84 (2019).
Zheng, X. et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling. Mol. Cancer 18, 47 (2019).
Pan, Z. et al. A novel protein encoded by exosomal CircATG4B induces oxaliplatin resistance in colorectal cancer by promoting autophagy. Adv. Sci. 9, e2204513 (2022).
Ashwal-Fluss, R. et al. circRNA biogenesis competes with pre-mRNA splicing. Mol. Cell. 56, 55–66 (2014).
He, A. T., Liu, J. L., Li, F. Y. & Yang, B. B. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct. Target. Ther. 6, 185 (2021).
Westholm, J. O. et al. Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. Cell Rep. 9, 1966–1980 (2014).
Du, W. et al. The circular RNA circSKA3 binds integrin β1 to induce invadopodium formation enhancing breast cancer invasion. Mol. Ther. 28, 1287–1298 (2020).
Song, R. J. et al. A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR. Mol. Cancer 22, 16 (2023).
Krug, L. M. Harnessing the immune system to treat cancer. J. Thorac. Oncol. 6, S77–S79 (2011).
Fink, K. Can we improve vaccine efficacy by targeting T and B cell repertoire convergence? Front. Immunol. 10, 110 (2019).
Francis, M. J. Recent advances in vaccine technologies. Vet. Clin. North Am. Small Anim. Pr. 48, 231 (2018).
Moore, J. & Klasse, P. COVID-19 vaccines: “warp speed” needs mind melds, not warped minds. J. Virol. 94, e01083–20 (2020).
Kouhpayeh, H. & Ansari, H. Adverse events following COVID-19 vaccination: a systematic review and meta-analysis. Int. Immunopharmacol. 109, 108906 (2022).
Koirala, A. et al. Vaccines for COVID-19: the current state of play. Paediatr. Respir. Rev. 35, 43–49 (2020).
Su, S., Du, L. Y. & Jiang, S. B. Learning from the past: development of safe and effective COVID-19 vaccines. Nat. Rev. Microbiol. 19, 211–219 (2021).
Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).
van Riel, D. & de Wit, E. Next-generation vaccine platforms for COVID-19. Nat. Mater. 19, 810–812 (2020).
He, Q. et al. mRNA cancer vaccines: advances, trends and challenges. Acta Pharm. Sin. B 12, 2969–2989 (2022).
Vishweshwaraiah, Y. L. & Dokholyan, N. V. mRNA vaccines for cancer immunotherapy. Front. Immunol. 13, 1029069 (2022).
Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618–630 (2010).
Jackson, N. A. C. et al. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).
Vergnes, J. N. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 384, 1577–1577 (2021).
Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).
Chen, C. et al. A flexible, efficient, and scalable platform to produce circular RNAs as new therapeutics. Preprint at https://www.biorxiv.org/content/10.1101/2022.05.31.494115v2 (2022).
Huang, K. et al. Delivery of Circular mRNA via degradable lipid nanoparticles against SARS-CoV-2 delta variant. Preprint at https://www.biorxiv.org/content/biorxiv/early/2022/05/12/2022.05.12.491597.full.pdf (2022).
Li, H. J. et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics 12, 6422–6436 (2022).
Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728 (2022).
Seephetdee, C. et al. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antivir. Res. 204, 105370 (2022).
Zhang, N. N. et al. A thermostable mRNA vaccine against COVID-19. Cell 182, 1271 (2020).
Rezaian, M. A. Synthesis of infectious viroids and other circular RNAs. Curr. Issues Mol. Biol. 1, 13–20 (1999).
Enuka, Y. et al. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 44, 1370–1383 (2016).
Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).
Kariko, K., Buckstein, M., Ni, H. P. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
Nallagatla, S. R., Toroney, R. & Bevilacqua, P. C. Regulation of innate immunity through RNA structure and the protein kinase PKR. Curr. Opin. Struct. Biol. 21, 119–127 (2011).
Wesselhoeft, R. A. et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol. Cell. 74, 508 (2019).
Kameda, S., Ohno, H. & Saito, H. Synthetic circular RNA switches and circuits that control protein expression in mammalian cells. Nucleic Acids Res. 51, e24 (2023).
Smith, E. L., Zamarin, D. & Lesokhin, A. M. Harnessing the immune system for cancer therapy. Curr. Opin. Oncol. 26, 600–607 (2014).
Benson, R. A. et al. Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo. eLife 4, e06994 (2015).
Qin, M. M. et al. Current perspectives on B lymphocytes in the immunobiology of hepatocellular carcinoma. Front. Oncol. 11, 647854 (2021).
Sanger, H. et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc. Natl Acad. Sci. USA 73, 3852–3856 (1976).
Hsu, M. T. & Coca-Prados, M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 280, 339–340 (1979).
Arnberg, A. C. et al. Some yeast mitochondrial RNAs are circular. Cell 19, 313–319 (1980).
Kos, A. et al. The hepatitis delta (delta) virus possesses a circular RNA. Nature 323, 558–560 (1986).
Price, J. V., Engberg, J. & Cech, T. R. 5′ exon requirement for self-splicing of the Tetrahymena thermophila pre-ribosomal RNA and identification of a cryptic 5′ splice site in the 3′ exon. J. Mol. Biol. 196, 49–60 (1987).
Salzman, J. et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE 7, e30733 (2012).
Surono, A. et al. Circular dystrophin RNAs consisting of exons that were skipped by alternative splicing. Hum. Mol. Genet. 8, 493–500 (1999).
Jeck, W. R. et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Rna 19, 141–157 (2013).
Hansen, T. B. et al. Natural RNA circles function as efficient microRNA sponges. Nature 495, 384–388 (2013).
Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338 (2013).
Wang, Y. & Wang, Z. F. Efficient backsplicing produces translatable circular mRNAs. Rna 21, 172–179 (2015).
Du, W. W. et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 24, 357–370 (2017).
Huang, A. Q. et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics 10, 3503–3517 (2020).
Xu, X. L. et al. CircRNA inhibits DNA damage repair by interacting with host gene. Mol. Cancer 19, 128 (2020).
Zhou, W. Y. et al. Circular RNA: metabolism, functions and interactions with proteins. Mol. Cancer 19, 172 (2020).
Grabowski, P. J., Zaug, A. J. & Cech, T. R. The intervening sequence of the ribosomal RNA precursor is converted to a circular RNA in isolated nuclei of Tetrahymena. Cell 23, 467–476 (1981).
Branch, A. D. et al. Cell-free circularization of viroid progeny RNA by an RNA ligase from wheat germ. Science 217, 1147–1149 (1982).
Puttaraju, M. & Been, M. D. Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons. Nucleic Acids Res. 20, 5357–5364 (1992).
Dolinnaya, N. G. et al. Oligonucleotide circularization by template-directed chemical ligation. Nucleic Acids Res. 21, 5403–5407 (1993).
Ford, E. & Ares, M. Jr. Synthesis of circular RNA in bacteria and yeast using RNA cyclase ribozymes derived from a group I intron of phage T4. Proc. Natl Acad. Sci. USA 91, 3117–3121 (1994).
Chen, C. & Sarnow, P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science 268, 415–417 (1995).
Perriman, R. & Ares, M. Jr. Circular mRNA can direct translation of extremely long repeating-sequence proteins in vivo. Rna 4, 1047–1054 (1998).
Kariko, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).
Weingarten-Gabbay, S. et al. Systematic discovery of cap-independent translation sequences in human and viral genomes. Science 351, aad4939 (2016).
Meganck, R. M. et al. Engineering highly efficient backsplicing and translation of synthetic circRNAs. Mol. Ther. Nucleic Acids 23, 821–834 (2021).
Chen, Y. G. et al. N6-methyladenosine modification controls circular RNA immunity. Mol. Cell. 76, 96 (2019).
Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262–272 (2023).
Yang, J. L. et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Mol. Ther. Nucleic Acids 30, 184–197 (2022).
Liu, X. et al. Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation. Mol. Ther. Nucleic Acids 13, 312–321 (2018).
Wang, Z. et al. Synthetic circular multi-miR sponge simultaneously inhibits miR-21 and miR-93 in esophageal carcinoma. Lab. Investig. 99, 1442–1453 (2019).
Lavenniah, A. et al. Engineered circular RNA sponges act as miRNA inhibitors to attenuate pressure overload-induced cardiac hypertrophy. Mol. Ther. 28, 1506–1517 (2020).
Schreiner, S., Didio, A., Hung, L. H. & Bindereif, A. Design and application of circular RNAs with protein-sponge function. Nucleic Acids Res. 48, 12326–12335 (2020).
Rybak-Wolf, A. et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol. Cell. 58, 870–885 (2015).
Chen, C. K. et al. Structured elements drive extensive circular RNA translation. Mol. Cell. 81, 4300 (2021).
Abe, N. et al. Rolling circle amplification in a prokaryotic translation system using small circular. Rna. Angew. Chem. Int. Ed. Engl. 52, 7004–7008 (2013).
Abe, N. et al. Rolling circle translation of circular RNA in living human cells. Sci. Rep. 5, 16435 (2015).
Chen, C. Y., Yang, Y. & Wang, Z. F. Study of circular RNA translation using reporter systems in living cells. Methods 196, 113–120 (2021).
Lu, Y. Q. et al. Translation role of circRNAs in cancers. J. Clin. Lab. Anal. 35, e23866 (2021).
Khodadoust, M. S. et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543, 723 (2017).
Andrews, S. J. & Rothnagel, J. A. Emerging evidence for functional peptides encoded by short open reading frames. Nat. Rev. Genet. 15, 193–204 (2014).
Olexiouk, V., Van Criekinge, W. & Menschaert, G. An update on sORFs.org: a repository of small ORFs identified by ribosome profiling. Nucleic Acids Res. 46, D497–D502 (2018).
Blyn, L. B., Towner, J. S., Semler, B. L. & Ehrenfeld, E. Requirement of poly(rC) binding protein 2 for translation of poliovirus RNA. J. Virol. 71, 6243–6246 (1997).
Gamarnik, A. V. & Andino, R. Two functional complexes formed by KH domain containing proteins with the 5′ noncoding region of poliovirus RNA. Rna 3, 882–892 (1997).
Walter, B. L., Nguyen, J. H., Ehrenfeld, E. & Semler, B. L. Differential utilization of poly(rC) binding protein 2 in translation directed by picornavirus IRES elements. Rna 5, 1570–1585 (1999).
Mangus, D. A., Evans, M. C. & Jacobson, A. Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol. 4, 223 (2003).
Jackson, R. J., Hellen, C. U. T. & Pestova, T. V. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 11, 113–127 (2010).
Wang, X. et al. N-6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505, 117 (2014).
Shi, H. L. et al. YTHDF3 facilitates translation and decay of N-6-methyladenosine-modified RNA. Cell Res. 27, 315–328 (2017).
Yang, Y. et al. Extensive translation of circular RNAs driven by N-6-methyladenosine. Cell Res. 27, 626–641 (2017).
Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456–1464 (2015).
Garcia, M. et al. Regulation and function of the cytosolic viral RNA sensor RIG-I in pancreatic beta cells. Biochim Biophys. Acta 1793, 1768–1775 (2009).
Thoresen, D. et al. The molecular mechanism of RIG-I activation and signaling. Immunol. Rev. 304, 154–168 (2021).
Wu, J. X. & Chen, Z. J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32, 461–488 (2014).
Chen, N. H. et al. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69, 297–304 (2017).
Linares-Fernandez, S., Lacroix, C., Exposito, J. Y. & Verrier, B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol. Med. 26, 311–323 (2020).
Walther, K. & Schulte, L. N. The role of lncRNAs in innate immunity and inflammation. RNA Biol. 18, 587–603 (2021).
Chen, Y. G. et al. Sensing self and foreign circular RNAs by intron identity. Mol. Cell. 67, 228 (2017).
Roundtree, I. A., Evans, M. E., Pan, T. & He, C. Dynamic RNA modifications in gene expression regulation. Cell 169, 1187–1200 (2017).
Zhao, W. et al. High-throughput microarray reveals the epitranscriptome-wide landscape of m(6)A-modified circRNA in oral squamous cell carcinoma. BMC Genomics 23, 661 (2022).
Vicens, Q. et al. Toward predicting self-splicing and protein-facilitated splicing of group I introns. Rna 14, 2013–2029 (2008).
Linder, B. et al. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat. Methods 12, 767–114 (2015).
Bai, Y. et al. Research progress on circular RNA vaccines. Front. Immunol. 13, 1091797 (2023).
Ji, P. F. et al. Expanded expression landscape and prioritization of circular RNAs in mammals. Cell Rep. 26, 3444 (2019).
Dolinnaya, N. G., Sokolova, N. I., Ashirbekova, D. T. & Shabarova, Z. A. The use of BrCN for assembling modified DNA duplexes and DNA-RNA hybrids; comparison with water-soluble carbodiimide. Nucleic Acids Res. 19, 3067–3072 (1991).
Fantoni, N. Z., El-Sagheer, A. H. & Brown, T. A Hitchhiker’s guide to click-chemistry with nucleic acids. Chem. Rev. 121, 7122–7154 (2021).
Nakamoto, K. et al. Chemically synthesized circular RNAs with phosphoramidate linkages enable rolling circle translation. Chem. Commun. 56, 6217–6220 (2020).
Nakamoto, K. & Abe, H. Chemical synthesis of circular RNAs with phosphoramidate linkages for rolling-circle translation. Curr. Protoc. 1, e43 (2021).
Kaur, J., Saxena, M. & Rishi, N. An overview of recent advances in biomedical applications of click chemistry. Bioconjugate Chem. 32, 1455–1471 (2021).
Lee, K. H., Kim, S. & Lee, S. W. Pros and cons of in vitro methods for circular RNA preparation. Int. J. Mol. Sci. 23, 13247 (2022).
Popow, J., Schleiffer, A. & Martinez, J. Diversity and roles of (t)RNA ligases. Cell. Mol. Life Sci. 69, 2657–2670 (2012).
Wood, W. B. & Revel, H. R. The genome of bacteriophage T4. Bacteriol. Rev. 40, 847–868 (1976).
Wang, Y. M. & Silverman, S. K. A general two-step strategy to synthesize lariat RNAs. Rna 12, 313–321 (2006).
Costello, A., Lao, N. T., Barron, N. & Clynes, M. Reinventing the wheel: synthetic circular RNAs for mammalian cell engineering. Trends Biotechnol. 38, 217–230 (2020).
Krug, M. & Uhlenbeck, O. C. Reversal of T4 RNA ligase. Biochemistry 21, 1858–1864 (1982).
Chen, H. et al. Preferential production of RNA rings by T4 RNA ligase 2 without any splint through rational design of precursor strand. Nucleic Acids Res. 48, e54 (2020).
Cheng, K. et al. RNA ligation of very small pseudo nick structures by T4 RNA ligase 2, leading to efficient production of versatile RNA rings. RSC Adv. 9, 8620–8627 (2019).
Romaniuk, P. & Uhlenbeck, O. Joining of RNA molecules with RNA ligase. Methods Enzymol. 100, 52–59 (1983).
Wang, L. & Ruffner, D. E. Oligoribonucleotide circularization by ‘template-mediated’ ligation with T4 RNA ligase: synthesis of circular hammerhead ribozymes. Nucleic Acids Res. 26, 2502–2504 (1998).
Lang, K. & Micura, R. The preparation of site-specifically modified riboswitch domains as an example for enzymatic ligation of chemically synthesized RNA fragments. Nat. Protoc. 3, 1457–1466 (2008).
Abe, N., Kodama, A. & Abe, H. Preparation of circular RNA in vitro. Methods Mol. Biol. 1724, 181–192 (2018).
Liu, C. X. et al. RNA circles with minimized immunogenicity as potent PKR inhibitors. Mol. Cell. 82, 420 (2022).
Petkovic, S. & Muller, S. RNA circularization strategies in vivo and in vitro. Nucleic Acids Res. 43, 2454–2465 (2015).
Qi, Y. F. et al. Engineering circular RNA regulators to specifically promote circular RNA production. Theranostics 11, 7322–7336 (2021).
Rausch, J. W. et al. Characterizing and circumventing sequence restrictions for synthesis of circular RNA in vitro. Nucleic Acids Res. 49, e35 (2021).
Zimmerly, S. & Semper, C. Evolution of group II introns. Mobile DNA 6, 1–19 (2015).
Jarrell, K. A. Inverse splicing of a group II intron. Proc. Natl Acad. Sci. USA 90, 8624–8627 (1993).
Mikheeva, S., Hakim-Zargar, M., Carlson, D. & Jarrell, K. Use of an engineered ribozyme to produce a circular human exon. Nucleic Acids Res. 25, 5085–5094 (1997).
Murray, H. L. et al. Excision of group II introns as circles. Mol. Cell. 8, 201–211 (2001).
Haurwitz, R. E. et al. Sequence- and structure-specific RNA processing by a CRISPR endonuclease. Science 329, 1355–1358 (2010).
Borchardt, E. K. et al. Inducing circular RNA formation using the CRISPR endoribonuclease Csy4. Rna 23, 619–627 (2017).
Roth, A. et al. A widespread self-cleaving ribozyme class is revealed by bioinformatics. Nat. Chem. Biol. 10, 56–92 (2014).
Litke, J. L. & Jaffrey, S. R. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat. Biotechnol. 37, 667 (2019).
Litke, J. L. & Jaffrey, S. R. Trans ligation of RNAs to generate hybrid circular RNAs using highly efficient autocatalytic transcripts. Methods 196, 104–112 (2021).
Lu, T., Klein, L. J., Ha, S. & Rustandi, R. R. High-resolution capillary electrophoresis separation of large RNA under non-aqueous conditions. J. Chromatogr. A. 1618, 460875 (2020).
Green, M. R. & Sambrook, J. Separation of RNA according to size: electrophoresis of RNA through denaturing urea polyacrylamide gels. Cold Spring Harb. Protoc. 2021, 10.1101 (2021).
Breuer, J. & Rossbach, O. Production and purification of artificial circular RNA sponges for application in molecular biology and medicine. Methods Protoc. 3, 42 (2020).
Abe, B. T. et al. Circular RNA migration in agarose gel electrophoresis. Mol. Cell. 82, 1768 (2022).
Suzuki, H. et al. Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res. 34, e63 (2006).
Suzuki, H. & Tsukahara, T. A view of pre-mRNA splicing from RNase R resistant RNAs. Int. J. Mol. Sci. 15, 9331–9342 (2014).
Vincent, H. A. & Deutscher, M. P. Substrate recognition and catalysis by the exoribonuclease RNase R. J. Biol. Chem. 281, 29769–29775 (2006).
Xiao, M. S. & Wilusz, J. E. An improved method for circular RNA purification using RNase R that efficiently removes linear RNAs containing G-quadruplexes or structured 3 ‘ ends. Nucleic Acids Res. 47, 8755–8769 (2019).
Kwok, C. K., Marsico, G. & Balasubramanian, S. Detecting RNA G-quadruplexes (rG4s) in the transcriptome. Cold Spring Harbor. Perspect. Biol. 10, a032283 (2018).
Vincent, H. A. & Deutscher, M. P. Insights into how RNase R degrades structured RNA: analysis of the nuclease domain. J. Mol. Biol. 387, 570–583 (2009).
Zhang, Y., Yang, L. & Chen, L.-L. Characterization of circular RNAs. Methods Mol. Biol. 2372, 179–192 (2021).
Yang, Y. L. et al. Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens. Vaccine 33, 1143–1150 (2015).
Garcia-Canas, V., Lorbetskie, B. & Girard, M. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. J. Chromatogr. A. 1123, 225–232 (2006).
Garcia-Canas, V. et al. Approach to the profiling and characterization of influenza vaccine constituents by the combined use of size-exclusion chromatography, gel electrophoresis and mass spectrometry. Biologicals 38, 294–302 (2010).
Li, Y. D. et al. Coronavirus vaccine development: from SARS and MERS to COVID-19. J. Biomed. Sci. 27, 104 (2020).
Li, M. Y. et al. The nano delivery systems and applications of mRNA. Eur. J. Med. Chem. 227, 113910 (2022).
Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022).
Gregoriadis, G. Liposomes in drug delivery: how it all happened. Pharmaceutics 8, 19 (2016).
Harashima, H., Sakata, K., Funato, K. & Kiwada, H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res. 11, 402–406 (1994).
Tenchov, R., Bird, R., Curtze, A. E. & Zhou, Q. Q. Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15, 16982–17015 (2021).
Reichmuth, A. M. et al. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 7, 319–334 (2016).
Ramachandran, S., Satapathy, S. R. & Dutta, T. Delivery Strategies for mRNA Vaccines. Pharm. Med. 36, 11–20 (2022).
Evers, M. J. W. et al. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods 2, 1700375 (2018).
Cheng, X. W. & Lee, R. J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Deliv. Rev. 99, 129–137 (2016).
Tang, B., Qian, Y. & Fang, G. H. Development of lipid-polymer hybrid nanoparticles for improving oral absorption of enoxaparin. Pharmaceutics 12, 607 (2020).
Lou, G. et al. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: the impact of cationic lipid selection. J. Control. Release 325, 370–379 (2020).
Kedmi, R., Ben-Arie, N. & Peer, D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867–6875 (2010).
Suga, K. et al. Conformational change of single-stranded RNAs induced by liposome binding. Nucleic Acids Res. 39, 8891–8900 (2011).
Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017).
Malone, R. W. et al. Cationic liposome mediated transfection. Proc. Natl Acad. Sci. USA 86, 6077–6081 (1989).
Zhang, G. et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat. Med. 18, 307–314 (2012).
Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300–7306 (2015).
Sato, Y. et al. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo. J. Control. Release 295, 140–152 (2019).
Fan, N. et al. Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. Sci. Adv. 8, eabq3500, (2022).
Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).
McKinlay, C. J. et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc. Natl Acad. Sci. USA 114, E448–E456 (2017).
McKinlay, C. J. et al. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc. Natl Acad. Sci. USA 115, E5859–E5866 (2018).
Arteta, M. Y. et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA 115, E3351–E3360 (2018).
McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).
Wisse, E. et al. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193–1199 (2008).
Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217, 345–351 (2015).
Alden, M. et al. Intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 in vitro in human liver cell line. Curr. Issues Mol. Biol. 44, 1115–1126 (2022).
Chen, J. J. et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).
Long, J. R. et al. Novel ionizable lipid nanoparticles for SARS-CoV-2 Omicron mRNA delivery. Adv. Healthc. Mater. 12, e2202590 (2023).
Ding, Y. Y. et al. The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I-peptide complex formation. Nat. Immunol. 17, 1167 (2016).
Qiao, J. et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis. Cancer Cell 35, 901 (2019).
Midoux, P. & Pichon, C. Lipid-based mRNA vaccine delivery systems. Expert Rev. Vaccines 14, 221–234 (2015).
Diken, M. et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 18, 702–708 (2011).
Selmi, A. et al. Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunol. Immunother. 65, 1075–1083 (2016).
Probst, J. et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 14, 1175–1180 (2007).
Edwards, D. K. et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J. Transl. Med. 15, 1 (2017).
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222 (2017).
Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419 (2018).
Newman, J. H. et al. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc. Natl Acad. Sci. USA 117, 1119–1128 (2020).
Nam, J., Son, S., Park, K. S. & Moon, J. J. Photothermal therapy combined with neoantigen cancer vaccination for effective immunotherapy against large established tumors and distant metastasis. Adv. Ther. 4, 2100093 (2021).
Loan Young, T., Chang Wang, K., James Varley, A. & Li, B. Clinical delivery of circular RNA: lessons learned from RNA drug development. Adv. Drug Delivery Rev. 197, 114826 (2023).
Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021).
Zuo, X. et al. Recent advances in nanomaterials for asthma treatment. Int. J. Mol. Sci. 23, 14427 (2022).
Brito, L. A. et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22, 2118–2129 (2014).
Teixeira, H. F. et al. Cationic nanoemulsions as nucleic acids delivery systems. Int. J. Pharm. 534, 356–367 (2017).
Amiri, A. et al. Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications. J. Transl. Med. 20, 125 (2022).
Tsai, S. J., Guo, C., Atai, N. A. & Gould, S. J. Exosome-mediated mRNA delivery for SARS-CoV-2 vaccination. Preprint at https://www.biorxiv.org/content/10.1101/2020.11.06.371419v2 (2020).
Schumann, C. et al. Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. Theranostics 8, 5276–5288 (2018).
Lonez, C., Vandenbranden, M. & Ruysschaert, J. M. Cationic lipids activate intracellular signaling pathways. Adv. Drug Deliv. Rev. 64, 1749–1758 (2012).
Wissing, S. A., Kayser, O. & Muller, R. H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257–1272 (2004).
Montoto, S. S., Muraca, G. & Ruiz, M. E. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front. Mol. Biosci. 7, 587997 (2020).
Akbari, J. et al. Solid lipid nanoparticles and nanostructured lipid carriers: a review of the methods of manufacture and routes of administration. Pharm. Dev. Technol. 27, 525–544 (2022).
Khan, S. et al. Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. Int. J. Pharm. Investig. 5, 182–191 (2015).
Mendoza-Munoz, N. et al. Solid lipid nanoparticles: an approach to improve oral drug delivery. J. Pharm. Pharm. Sci. 24, 509–532 (2021).
Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465–1468 (1990).
Martinon, F. et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23, 1719–1722 (1993).
Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).
Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 383, 1544–1555 (2020).
Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).
Tai, W. B. et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 30, 932–935 (2020).
Yan, R. et al. Drug repositioning for hand, foot, and mouth disease. Viruses 15, 75 (2023).
Mummert, A. et al. A perspective on multiple waves of influenza pandemics. PLoS ONE 8, e60343 (2013).
Cao, C. X. et al. Analysis of spatiotemporal characteristics of pandemic SARS spread in Mainland China. Biomed. Res. Int. 2016, 7247983 (2016).
Feng, R. D. et al. RNA therapeutics-research and clinical advancements. Front. Mol. Biosci. 8, 710738 (2021).
Punzo, O. et al. Clinical characteristics of individuals under 40 years of age who died with COVID-19 in Italy. J. Med. Virol. 93, 1932–1936 (2021).
Zhou, Y. T. et al. COVID-19 is distinct from SARS-CoV-2-negative community-acquired pneumonia. Front. Cell. Infect. Microbiol. 10, 322 (2020).
Noy-Porat, T. et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat. Commun. 11, 4303 (2020).
Tai, W. B. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol. Immunol. 17, 613–620 (2020).
Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467 (2022).
Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548 (2020).
Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501 (2020).
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260 (2020).
Sun, W. Q. et al. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct. Target. Ther. 6, 340 (2021).
Yang, L. et al. A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. Innovation 2, 100140 (2021).
Liu, L. M. et al. Circular RNAs: Isolation, characterization and their potential role in diseases. RNA Biol. 14, 1715–1721 (2017).
Li, H. M., Ma, X. L. & Li, H. G. Intriguing circles: conflicts and controversies in circular RNA research. Wiley Interdiscip. Rev. RNA 10, e1538 (2019).
Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569–1584 (2020).
Gomez, C. E. et al. Enhancement of the HIV-1-specific immune response induced by an mRNA vaccine through boosting with a poxvirus MVA vector expressing the same antigen. Vaccines 9, 959 (2021).
Espeseth, A. S. et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. NPJ Vaccines 5, 16 (2020).
Awasthi, S. et al. Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in models. J. Clin. Investig. 131, e152310 (2021).
Monslow, M. A. et al. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine 38, 5793–5802 (2020).
Aldrich, C. et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine 39, 1310–1318 (2021).
Webster, H. et al. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models. Vaccine 39, 5358–5367 (2021).
Lo, M. K. et al. Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters. J. Infect. Dis. 221, S493–S498 (2020).
Knudson, C. J. et al. Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection. Mol. Ther. 29, 2769–2781 (2021).
Wollner, C. J. et al. A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. J. Virol. 95, 10–1128 (2021).
Nahmad, A. D. et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat. Biotechnol. 40, 1241 (2022).
Schaefer-Babajew, D. et al. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature 613, 735–742 (2023).
Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110 (2020).
Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014 (2020).
Zhang, P. et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med. 27, 2234 (2021).
Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728 (2022).
Gilbert, P. B. et al. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat. Med. 28, 1924 (2022).
Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288 (2022).
Lu, J. J. et al. Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Front. Oncol. 13, 1133828 (2023).
Tang, H. J. et al. Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy. Gynecol. Oncol. 171, 49–58 (2023).
August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224 (2021).
Narayanan, E. et al. Rational design and in vivo characterization of mRNA-encoded broadly neutralizing antibody combinations against HIV-1. Antibodies 11, 67 (2022).
Vanover, D. et al. Nebulized mRNA-encoded antibodies protect hamsters from SARS-CoV-2 infection. Adv. Sci. 9, 1098302 (2022).
Huang, C. et al. Lipid nanoparticle delivery system for mRNA encoding B7H3-redirected bispecific antibody displays potent antitumor effects on malignant tumors. Adv. Sci. 10, e2205532 (2023).
Panova, E. A. et al. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A. Front. Immunol. 14, 1098302 (2023).
Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019).
Rastrelli, M., Tropea, S., Rossi, C. R. & Alaibac, M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo 28, 1005–1011 (2014).
Hughes, L. E. Epidemiology of melanoma. Lancet 1, 557 (1981).
Sekulovic, L. K. et al. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur. J. Cancer 104, 201–209 (2018).
Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396 (2016).
Kwak, M., Leick, K. M., Melssen, M. M. & Slingluff, C. L. Vaccine strategy in melanoma. Surg. Oncol. Clin. N. Am. 28, 337 (2019).
Cintolo, J. A. et al. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8(+) T cells that impact BRAF-mutant murine melanoma. Melanoma Res. 26, 1–11 (2016).
Liu, Q. et al. BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunol. Immunother. 67, 299–310 (2018).
Fijak, M., Bhushan, S. & Meinhardt, A. Immunoprivileged sites: the testis. Methods Mol. Biol. 677, 459–470 (2011).
Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015).
Dreno, B. et al. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 916–929 (2018).
Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747 (2013).
Depontieu, F. R. et al. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl Acad. Sci. USA 106, 12073–12078 (2009).
Petersen, J. et al. Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc. Natl Acad. Sci. USA 106, 2776–2781 (2009).
Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107 (2020).
Gress, R. E. et al. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part I. Biology of relapse after transplantation. Biol. Blood Marrow Transpl. 19, 1537–1545 (2013).
Vik-Mo, E. O. et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother. 62, 1499–1509 (2013).
Rittig, S. M. et al. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncoimmunology 5, e1108511 (2016).
Cafri, G. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Investig. 130, 5976–5988 (2020).
Amin, A. et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J. ImmunoTher. Cancer 3, 14 (2015).
Khoury, H. J. et al. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer 123, 3061–3072 (2017).
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P. & Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135–146 (2014).
Maniscalco, G. T. et al. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. Mult. Scler. Relat. Disord. 58, 103455 (2022).
Kyewski, B. & Derbinski, J. Self-representation in the thymus: an extended view. Nat. Rev. Immunol. 4, 688–698 (2004).
Romero, P. et al. The Human Vaccines Project: a roadmap for cancer vaccine development. Sci. Transl. Med. 8, 334ps9 (2016).
Kramps, T. et al. Introduction to RNA Vaccines. Methods Mol. Biol. 1499, 1–111 (2017).
Demaria, O. et al. Harnessing innate immunity in cancer therapy. Nature 574, 45–56 (2019).
Sun, H. Y. et al. Using PAMPs and DAMPs as adjuvants in cancer vaccines. Hum. Vaccin Immunother. 17, 5546–5557 (2021).
Chawla-Sarkar, M., Leaman, D. W. & Borden, E. C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 7, 1821–1831 (2001).
Spaapen, R. M. et al. Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature. J. Immunol. 193, 4254–4260 (2014).
Hotz, C. et al. Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl. Med. 13, 143–158 (2021).
Liu, J. Q. et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J. Control. Release 345, 306–313 (2022).
Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. L. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143–158 (2016).
Stewart, J. M. & Keselowsky, B. G. Combinatorial drug delivery approaches for immunomodulation. Adv. Drug Deliv. Rev. 114, 161–174 (2017).
Henriques-Normark, B. & Normark, S. Bacterial vaccines and antibiotic resistance. Ups. J. Med. Sci. 119, 205–208 (2014).
Maruggi, G. et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35, 361–368 (2017).
Guo, X. R. et al. PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro. Clin. Exp. Med. 15, 501–509 (2015).
Robinson, E. et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol. Ther. 26, 2034–2046 (2018).
Derdelinckx, J. et al. Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. J. Neuroinflammation 16, 167 (2019).
Anttila, V. et al. Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial. Mol. Ther. Methods Clin. Dev. 18, 464–472 (2020).
Flemming, A. mRNA vaccine shows promise in autoimmunity. Nat. Rev. Immunol. 21, 72–72 (2021).
Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145–153 (2021).
Ni, Z. X. et al. Circular forms of dedicator of cytokinesis 1 promotes breast cancer progression by derepressing never in mitosis related kinase 2 via sponging miR-128-3p. Environ. Toxicol. 11, 1–11 (2023).
Wang, Y. A. et al. The influence of circular RNAs on autophagy and disease progression. Autophagy 18, 240–253 (2022).
Arora, S. et al. Unravelling host-pathogen interactions: ceRNA network in SARS-CoV-2 infection (COVID-19). Gene 762, 145057 (2020).
Lai, M. et al. CircFAM114A2 inhibits the progression of hepatocellular carcinoma via miR-630/HHIP axis. Cancer Med. 12, 12553–12568 (2023).
Zhou, Y. et al. CircEPS15, as a sponge of MIR24-3p ameliorates neuronal damage in Parkinson disease through boosting PINK1-PRKN-mediated mitophagy. Autophagy 10, 1–18 (2023).
van Rooij, E. & Olson, E. N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11, 860–872 (2012).
Gebert, L. F. R. et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 42, 609–621 (2014).
Rupaimoole, R. & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203–221 (2017).
Santer, L., Bar, C. & Thum, T. Circular RNAs: a novel class of functional RNA molecules with a therapeutic perspective. Mol. Ther. 27, 1350–1363 (2019).
Zhang, Y. et al. Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs. Genome Biol. 22, 41 (2021).
Jost, I. et al. Functional sequestration of microRNA-122 from Hepatitis C virus by circular RNA sponges. RNA Biol. 15, 1032–1039 (2018).
Haga, C. L. et al. Rapid generation of miRNA inhibitor leads by bioinformatics and efficient high-throughput screening methods. Methods Mol. Biol. 1517, 179–198 (2017).
Griffiths-Jones, S. et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34, D140–D144 (2006).
Huang, H. Y., Chien, C. H., Jen, K. H. & Huang, H. D. RegRNA: an integrated web server for identifying regulatory RNA motifs and elements. Nucleic Acids Res. 34, W429–W434 (2006).
Hsu, S. D. et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 42, D78–D85 (2014).
Li, J. H. et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42, D92–D97 (2014).
Dudekulay, D. B. et al. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 13, 34–42 (2016).
Liu, Y. C. et al. CircNet: a database of circular RNAs derived from transcriptome sequencing data. Nucleic Acids Res. 44, D209–D215 (2016).
Liu, M. et al. Circbank: a comprehensive database for circRNA with standard nomenclature. RNA Biol. 16, 899–905 (2019).
Ebert, M. S. & Sharp, P. A. MicroRNA sponges: progress and possibilities. Rna 16, 2043–2050 (2010).
Hansen, T. B. et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. EMBO J. 30, 4414–4422 (2011).
Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721–726 (2007).
Gentner, B. et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 6, 63–66 (2009).
Otaegi, G., Pollock, A. & Sun, T. An optimized sponge for microRNA miR-9 affects spinal motor neuron development in vivo. Front. Neurosci. 5, 146 (2012).
Rehmsmeier, M., Steffen, P., Hochsmann, M. & Giegerich, R. Fast and effective prediction of microRNA/target duplexes. Rna 10, 1507–1517 (2004).
Kruger, J. & Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34, W451–W454 (2006).
Begum, S., Yiu, A., Stebbing, J. & Castellano, L. Novel tumour suppressive protein encoded by circular RNA, circ-SHPRH, in glioblastomas. Oncogene 37, 4055–4057 (2018).
Holtkamp, S. et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009–4017 (2006).
Kim, K. Q. et al. N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products. Cell Rep. 40, 111300 (2022).
Mokuda, S. et al. N-1-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes. Cytotechnology 74, 503–514 (2022).
Anderson, B. R. et al. Nucleoside modifications in RNA limit activation of 2’-5’-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 39, 9329–9338 (2011).
Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731–745 (2009).
Anderson, B. R. et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38, 5884–5892 (2010).
Park, O. H. et al. Endoribonucleolytic cleavage of m(6)A-containing RNAs by RNase P/MRP complex. Mol. Cell. 74, 494 (2019).
Zhang, L. L. et al. The role of N-6-methyladenosine (m(6)A) modification in the regulation of circRNAs. Mol. Cancer 19, 105 (2020).
Qiu, Z. et al. Clean-PIE: a novel strategy for efficiently constructing precise circRNA with thoroughly minimized immunogenicity to direct potent and durable protein expression. Preprint at https://www.biorxiv.org/content/10.1101/2022.06.20.496777v2 (2022).
Chen, S. J. et al. Widespread and functional RNA circularization in localized prostate cancer. Cell 176, 831 (2019).
Jagtap, U., Anderson, E. S. & Slack, F. J. The emerging value of circular noncoding RNA research in cancer diagnosis and treatment. Cancer Res. 83, 809–813 (2023).